Drug intelligence / Profile preview

KR23248

Development stage: Phase 1
Lead developer: Jiangxi Kerui Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

KR23248 is an investigational pharmaceutical candidate being developed by Jiangxi Kvvit Pharmaceutical Co., Ltd. It is currently in early-stage clinical development, with a Phase I clinical trial conducted in China to evaluate its safety, tolerability, and pharmacokinetic profile in healthy adult subjects. The drug is administered orally in capsule form. While specific details regarding its molecular target and primary therapeutic indication have not been widely disclosed in public clinical trial registries, it is being evaluated for its potential as a systemic therapeutic agent.

Beyond the preview

Go deeper on KR23248.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KR23248.

Explore the full profile